DK2817333T3 - Bispecifikke, asymmetriske igg4-antistoffer - Google Patents

Bispecifikke, asymmetriske igg4-antistoffer Download PDF

Info

Publication number: DK2817333T3
Authority: DK; Denmark
Prior art keywords: bispecific; asymmetric; igg4 antibodies; igg4; antibodies
Prior art date: 2012-02-22

Application number

DK13707824.2T

Other languages

English (en)

Inventor

David Paul Humphreys

Shirley Jane Peters

Original Assignee

UCB Biopharma SRL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-02-22

Filing date

2013-02-22

Publication date

2020-03-16

2013-02-22 Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL

2020-03-16 Application granted granted Critical

2020-03-16 Publication of DK2817333T3 publication Critical patent/DK2817333T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Otolaryngology (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Obesity (AREA)

DK13707824.2T 2012-02-22 2013-02-22 Bispecifikke, asymmetriske igg4-antistoffer DK2817333T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1203071.4A GB201203071D0 (en)	2012-02-22	2012-02-22	Biological products
PCT/EP2013/053615 WO2013124451A1 (en)	2012-02-22	2013-02-22	Sequence symmetric modified igg4 bispecific antibodies

Publications (1)

Publication Number	Publication Date
DK2817333T3 true DK2817333T3 (da)	2020-03-16

Family

ID=45940034

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK13707824.2T DK2817333T3 (da)	2012-02-22	2013-02-22	Bispecifikke, asymmetriske igg4-antistoffer

Country Status (15)

Country	Link
US (1)	US9902768B2 (da)
EP (2)	EP3670531A1 (da)
JP (3)	JP6308953B2 (da)
KR (2)	KR102077332B1 (da)
CN (1)	CN104245729B (da)
AU (2)	AU2013224004B2 (da)
CA (1)	CA2865261A1 (da)
DK (1)	DK2817333T3 (da)
EA (1)	EA033720B1 (da)
ES (1)	ES2773123T3 (da)
GB (1)	GB201203071D0 (da)
IL (2)	IL234107B (da)
MX (1)	MX356301B (da)
SG (1)	SG11201404900YA (da)
WO (1)	WO2013124451A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201014033D0 (en)	2010-08-20	2010-10-06	Ucb Pharma Sa	Biological products
CA2817964C (en)	2010-11-17	2018-06-12	Chugai Seiyaku Kabushiki Kaisha	Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
GB201203071D0 (en)	2012-02-22	2012-04-04	Ucb Pharma Sa	Biological products
GB201203051D0 (en) *	2012-02-22	2012-04-04	Ucb Pharma Sa	Biological products
KR101895634B1 (ko)	2013-05-31	2018-09-05	한미약품 주식회사	변이된 힌지 영역을 포함하는 IgG4 Fc 단편
GB201414823D0 (en) *	2014-08-20	2014-10-01	Argen X Bv	Multispecific antibodies
WO2016118577A1 (en) *	2015-01-22	2016-07-28	Medimmune, Llc	Thymosin-beta-four fusion proteins
TWI691512B (zh) *	2015-02-20	2020-04-21	日商橘生藥品工業股份有限公司	Ｆｃ融合高親和性ＩｇＥ受體α鏈
MY191081A (en)	2015-07-23	2022-05-30	Boehringer Ingelheim Int	Compound targetting il-23a and b-cell activating factor (baff) and uses thereof
JP7026613B2 (ja) *	2015-08-07	2022-02-28	イマジナブ・インコーポレーテッド	標的分子に対する抗原結合コンストラクト
JP6954842B2 (ja) *	2015-12-25	2021-10-27	中外製薬株式会社	増強された活性を有する抗体及びその改変方法
KR102771920B1 (ko) *	2016-02-09	2025-02-25	브라코 스위스 에스.에이.	셀렉틴 표적화를 위한 재조합 키메라 단백질
MX2018012648A (es)	2016-04-28	2019-01-30	Chugai Pharmaceutical Co Ltd	Preparaciones que contienen anticuerpos.
BR112019001179A2 (pt)	2016-07-29	2019-04-30	Chugai Seiyaku Kabushiki Kaisha	anticorpo biespecífico que exibe atividade alternativa aumentada de função de cofator fviii
US11254753B2 (en) *	2016-10-06	2022-02-22	Glaxosmithkline Intellectual Property Development Limited	Antibodies with reduced binding to process impurities
WO2018081448A1 (en)	2016-10-26	2018-05-03	The Board Of Trustees Of The Leland Stanford Junior University	Modified immunoglobulin hinge regions to reduce hemagglutination
EP4467565A3 (en)	2016-12-21	2025-03-12	Amgen Inc.	Anti-tnf alpha antibody formulations
US11266745B2 (en)	2017-02-08	2022-03-08	Imaginab, Inc.	Extension sequences for diabodies
EP3606952A1 (en)	2017-04-07	2020-02-12	Miltenyi Biotec GmbH	POLYPEPTIDES WITH MUTANT HUMAN IgG4
WO2018218056A1 (en) *	2017-05-25	2018-11-29	Birstol-Myers Squibb Company	Antibodies comprising modified heavy constant regions
US20210403573A1 (en)	2017-06-22	2021-12-30	INSERM (Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
UA128389C2 (uk)	2017-09-29	2024-07-03	Чугаі Сейяку Кабусікі Кайся	Мультиспецифічна антигензв'язувальна молекула, яка має активність заміщувати кофакторну функцію фактора коагуляції крові viii (fviii), та фармацевтичний склад, який містить згадану молекулу як активний інгредієнт
MX2020003472A (es)	2017-11-01	2020-08-03	Chugai Pharmaceutical Co Ltd	Variante e isoforma de anticuerpos con actividad biologica reducida.
US11779649B2 (en) *	2018-12-21	2023-10-10	Novartis Ag	Antibodies to PMEL17 and conjugates thereof
SG11202107257UA (en)	2019-01-03	2021-07-29	Inst Nat Sante Rech Med	Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
AU2020257748A1 (en) *	2019-04-19	2021-11-18	Chugai Seiyaku Kabushiki Kaisha	Chimeric receptor recognizing modification site of antibody
AU2020273903B2 (en) *	2019-05-14	2024-05-09	Progen Co., Ltd.	Novel modified immunoglobulin Fc-fusion protein and use thereof
CN114258401B (zh)	2019-07-16	2025-08-12	Inserm(法国国家健康医学研究院)	对cd38具有特异性的抗体及其用途
US11717577B2 (en)	2019-07-18	2023-08-08	Hanmi Pharm. Co., Ltd.	Method for preparing long-acting drug conjugate through preparation of intermediate
US20250270325A1 (en) *	2020-03-31	2025-08-28	Medimmune, Llc	Stabilized igg4 antibodies and uses thereof
IL298114A (en) *	2020-05-12	2023-01-01	Lyell Immunopharma Inc	Chimeric antigen receptor spacers
CN114106180B (zh) *	2021-12-13	2023-07-28	中国药科大学	一种单克隆抗体及其应用
WO2025120015A1 (en)	2023-12-06	2025-06-12	Institut National de la Santé et de la Recherche Médicale	Cd5 targeting antibodies with depleting and t or b-cell activation effects
WO2025218739A1 (en) *	2024-04-17	2025-10-23	Jw Therapeutics R & D (Shanghai) Co., Ltd.	Polypeptide systems

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
DK336987D0 (da)	1987-07-01	1987-07-01	Novo Industri As	Immobiliseringsmetode
GB8719042D0 (en)	1987-08-12	1987-09-16	Parker D	Conjugate compounds
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5677425A (en) *	1987-09-04	1997-10-14	Celltech Therapeutics Limited	Recombinant antibody
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
AU4308689A (en)	1988-09-02	1990-04-02	Protein Engineering Corporation	Generation and selection of recombinant varied binding proteins
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
ES2052027T5 (es)	1988-11-11	2005-04-16	Medical Research Council	Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
AU7247191A (en)	1990-01-11	1991-08-05	Molecular Affinities Corporation	Production of antibodies using gene libraries
US5780225A (en)	1990-01-12	1998-07-14	Stratagene	Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
CA2090126C (en)	1990-08-02	2002-10-22	John W. Schrader	Methods for the production of proteins with a desired function
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69127627T2 (de)	1990-08-29	1998-02-19	Genpharm Int	Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
DE69129154T2 (de)	1990-12-03	1998-08-20	Genentech, Inc., South San Francisco, Calif.	Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ATE414768T1 (de)	1991-04-10	2008-12-15	Scripps Research Inst	Bibliotheken heterodimerer rezeptoren mittels phagemiden
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
GB9120467D0 (en)	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
ES2341666T3 (es)	1991-12-02	2010-06-24	Medimmune Limited	Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
EP0733070A1 (en)	1993-12-08	1996-09-25	Genzyme Corporation	Process for generating specific antibodies
DE69531148T2 (de)	1994-01-31	2004-04-29	Trustees Of Boston University, Boston	Bibliotheken aus polyklonalen antikörpern
FR2716640B1 (fr)	1994-02-28	1996-05-03	Procedes Machines Speciales	Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en)	1994-06-10	1996-05-14	Dade International Inc.	Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja)	1996-01-24	1999-11-15	チッソ株式会社	アクリロキシプロピルシランの製造方法
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
US20060228364A1 (en)	1999-12-24	2006-10-12	Genentech, Inc.	Serum albumin binding peptides for tumor targeting
US6908963B2 (en)	2001-10-09	2005-06-21	Nektar Therapeutics Al, Corporation	Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
AU2003244817B2 (en) *	2002-06-28	2010-08-26	Domantis Limited	Antigen-binding immunoglobulin single variable domains and dual-specific constructs
PT1570267E (pt)	2002-12-03	2012-01-03	Ucb Pharma Sa	Ensaio para a identificação de células produtoras de anticorpos
GB0312481D0 (en)	2003-05-30	2003-07-09	Celltech R&D Ltd	Antibodies
GB0315457D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
GB0315450D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
BRPI0511755A (pt)	2004-06-01	2008-01-02	Domantis Ltd	composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
US8911726B2 (en)	2004-09-22	2014-12-16	Kyowa Hakko Kirin Co., Ltd	Stabilized human Igg4 antibodies
GB0619291D0 (en)	2006-09-29	2006-11-08	Ucb Sa	Altered antibodies
EP2666787B1 (en)	2007-05-31	2022-02-09	Genmab A/S	STABLE IgG4 ANTIBODIES
KR102467302B1 (ko)	2007-09-26	2022-11-14	추가이 세이야쿠 가부시키가이샤	항체 정상영역 개변체
CA3053156A1 (en) *	2008-12-03	2010-06-10	Genmab A/S	Antibody variants having modifications in the constant region
EP3674317B1 (en) *	2009-03-19	2024-12-11	Chugai Seiyaku Kabushiki Kaisha	Antibody constant region variant
JP5889181B2 (ja) *	2010-03-04	2016-03-22	中外製薬株式会社	抗体定常領域改変体
DK3029066T3 (da) *	2010-07-29	2019-05-20	Xencor Inc	Antistoffer med modificerede isoelektriske punkter
GB201014033D0 (en) *	2010-08-20	2010-10-06	Ucb Pharma Sa	Biological products
RS60499B1 (sr) *	2011-12-20	2020-08-31	Medimmune Llc	Modifikovani polipeptidi za bispecifične skelete antitela
GB201203071D0 (en)	2012-02-22	2012-04-04	Ucb Pharma Sa	Biological products
GB201203051D0 (en) *	2012-02-22	2012-04-04	Ucb Pharma Sa	Biological products

2012
- 2012-02-22 GB GBGB1203071.4A patent/GB201203071D0/en not_active Ceased
2013
- 2013-02-22 KR KR1020147026255A patent/KR102077332B1/ko not_active Expired - Fee Related
- 2013-02-22 DK DK13707824.2T patent/DK2817333T3/da active
- 2013-02-22 JP JP2014558132A patent/JP6308953B2/ja not_active Expired - Fee Related
- 2013-02-22 CA CA2865261A patent/CA2865261A1/en not_active Abandoned
- 2013-02-22 CN CN201380019875.XA patent/CN104245729B/zh not_active Expired - Fee Related
- 2013-02-22 SG SG11201404900YA patent/SG11201404900YA/en unknown
- 2013-02-22 EP EP20150131.9A patent/EP3670531A1/en not_active Withdrawn
- 2013-02-22 AU AU2013224004A patent/AU2013224004B2/en not_active Ceased
- 2013-02-22 ES ES13707824T patent/ES2773123T3/es active Active
- 2013-02-22 KR KR1020207003554A patent/KR20200018707A/ko not_active Ceased
- 2013-02-22 EP EP13707824.2A patent/EP2817333B1/en active Active
- 2013-02-22 WO PCT/EP2013/053615 patent/WO2013124451A1/en not_active Ceased
- 2013-02-22 MX MX2014010021A patent/MX356301B/es active IP Right Grant
- 2013-02-22 EA EA201491571A patent/EA033720B1/ru not_active IP Right Cessation
- 2013-02-22 US US14/380,310 patent/US9902768B2/en not_active Expired - Fee Related
2014
- 2014-08-13 IL IL234107A patent/IL234107B/en active IP Right Grant
2018
- 2018-02-21 AU AU2018201233A patent/AU2018201233B2/en not_active Ceased
- 2018-03-13 JP JP2018045477A patent/JP2018127465A/ja active Pending
2019
- 2019-06-11 IL IL267225A patent/IL267225B/en active IP Right Grant
2020
- 2020-01-17 JP JP2020005926A patent/JP2020090514A/ja active Pending

Also Published As

Publication number	Publication date
IL234107A0 (en)	2014-09-30
CN104245729A (zh)	2014-12-24
EP3670531A1 (en)	2020-06-24
HK1202565A1 (en)	2015-10-02
JP2018127465A (ja)	2018-08-16
EA033720B1 (ru)	2019-11-20
MX356301B (es)	2018-05-23
SG11201404900YA (en)	2014-11-27
US20150017169A1 (en)	2015-01-15
AU2018201233A1 (en)	2018-03-15
CN104245729B (zh)	2018-11-16
GB201203071D0 (en)	2012-04-04
AU2013224004B2 (en)	2017-11-23
WO2013124451A1 (en)	2013-08-29
CA2865261A1 (en)	2013-08-29
KR102077332B1 (ko)	2020-02-17
AU2013224004A1 (en)	2014-09-18
IL267225B (en)	2020-11-30
AU2018201233B2 (en)	2019-06-06
EP2817333B1 (en)	2020-01-08
MX2014010021A (es)	2014-12-05
JP2015514684A (ja)	2015-05-21
JP6308953B2 (ja)	2018-04-11
IL267225A (en)	2019-08-29
ES2773123T3 (es)	2020-07-09
EA201491571A1 (ru)	2015-02-27
KR20140130711A (ko)	2014-11-11
US9902768B2 (en)	2018-02-27
KR20200018707A (ko)	2020-02-19
JP2020090514A (ja)	2020-06-11
EP2817333A1 (en)	2014-12-31
IL234107B (en)	2019-12-31

Publication	Publication Date	Title
HUS2400016I1 (hu)	2024-06-28	FCRN elleni antitestek
NO2023024I1 (no)	2023-05-30	Spesolimab, an ant-IL-36R antibody
IL267225B (en)	2020-11-30	Bispecific igg4 antibodies are asymmetrically sequenced
DK3156416T3 (da)	2020-02-24	Sekvenssymmetriske modificerede bispecifikke igg4-antistoffer
DK3378535T3 (da)	2023-01-30	Humanserede antistoffer, der genkender alpha-synuklein
DK2934584T3 (da)	2020-05-18	Anti-gdf15-antistoffer
HRP20181646T1 (hr)	2018-12-14	Konjugati pirolobenzodiazepin - anti-psma protutijela
DK2847231T3 (da)	2019-10-14	Multispecifikke monoklonale antistoffer
CO6811812A2 (es)	2013-12-16	Anticuerpo anti-b7-h3
BR112014024769A2 (pt)	2017-12-12	anticorpo humanizado tau
CR20140127A (es)	2014-08-20	Anticuerpo anti-abtcr
BR112014025037A2 (pt)	2018-07-31	anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
PL3088421T3 (pl)	2019-08-30	Przeciwciała monoklonalne do zastosowania w diagnostyce i leczeniu nowotworów i choroby autoimmunologicznej
HRP20181874T1 (hr)	2019-01-11	Anti-cxcr3 protutijela
DK2931748T3 (da)	2017-01-02	Bmp-6-antistoffer
DK3431504T3 (da)	2021-06-28	Antiphospholipase d4-antistof
DK3521315T3 (da)	2020-11-09	Anti-transglutaminase-2-antistoffer
DK2828292T3 (da)	2019-01-02	Jcv-neutraliserende antistoffer
DK2935330T3 (da)	2019-07-22	Anti-notch3-antistoffer
LT2814843T (lt)	2020-09-25	ŽMOGAUS MONOKLONINIAI ANTIKŪNAI, NEUTRALIZUOJANTYS IL-1ß
LT2742068T (lt)	2019-07-10	Nauji antikūnai prieš fosforilcholiną
CO6841994A2 (es)	2014-01-20	Anticuerpos
FR2978994B1 (fr)	2014-10-10	.
ES1074780Y (es)	2011-09-26	Columna-luminaria.
ES1074539Y (es)	2011-08-08	Mandil.